SCHEMBL2464518

SCHEMBL2464518

CNCc1ccc(Nc2cc(-c3ccc(F)c(NC(=O)c4ccc(C(C)(C)C)cc4)c3)n[nH]c2=O)nc1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
BTK Q06187 5/20 0.44
F10 P00742 1/20 0.41
NR1H4 Q96RI1 2/20 0.40
KIT P10721 1/20 0.40
SRC P12931 1/20 0.40
FLT3 P36888 1/20 0.40
ITK Q08881 1/20 0.40
PPARG P37231 1/20 0.40
MAPK14 Q16539 1/20 0.39
MAP3K5 Q99683 1/20 0.39
PARP1 P09874 4/20 0.38
DEGS1 O15121 1/20 0.37
PTGES O14684 1/20 0.36
GSK3B P49841 1/20 0.36
CLK2 P49760 1/20 0.36
HDAC1 Q13547 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9985063 0.84 BTK (0.45) BTKNR1H4KITSRCFLT3
SCHEMBL2459218 0.83 KIT (0.48) BTKNR1H4KITSRCFLT3
SCHEMBL2464995 0.82 BTK (0.48) BTKNR1H4KITSRCFLT3
SCHEMBL9985469 0.80 BTK (0.47) BTKNR1H4KITSRCFLT3
SCHEMBL2464067 0.76 BTK (0.58) BTKSRCGSK3BHDAC1
SCHEMBL9985149 0.76 BTK (0.43) BTKKITSRCFLT3ITK
SCHEMBL19981738 0.76 BTK (0.37) BTKNR1H4KITSRCFLT3
SCHEMBL2466471 0.75 BTK (0.45) BTKKITSRCFLT3ITK
SCHEMBL2459246 0.75 BTK (0.43) BTKKITSRCFLT3ITK
SCHEMBL2461857 0.75 BTK (0.43) BTKF10KITSRCFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8598174-B2 Pyridazinones, method of making, and method of use thereof GENETECH, INC. (US) 2013-12-03 US claimed
US-20110301145-A1 PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF Gilead Connecticut INc. (US) 2011-12-08 US claimed
EP-2365970-A1 Pyridazinones and their use as btk inhibitors CGI Pharmaceuticals, Inc. (US) 2011-09-21 EP claimed
WO-2010056875-A1 PYRIDAZINONES AND THEIR USE AS BTK INHIBITORS CGI PHARMACEUTICALS, INC. (US) 2010-05-20 WO claimed
EP-2365970-B1 PYRIDAZINONES AND THEIR USE AS BTK INHIBITORS GILEAD CONNECTICUT INC (US) 2018-03-21 EP disclosed
US-8598174-B2 Pyridazinones, method of making, and method of use thereof GENETECH, INC. (US) 2013-12-03 US disclosed
US-20110301145-A1 PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF Gilead Connecticut INc. (US) 2011-12-08 US disclosed
US-20110301145-A1 PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF Gilead Connecticut INc. (US) 2011-12-08 US disclosed
EP-2365970-A1 Pyridazinones and their use as btk inhibitors CGI Pharmaceuticals, Inc. (US) 2011-09-21 EP disclosed
WO-2010056875-A1 PYRIDAZINONES AND THEIR USE AS BTK INHIBITORS CGI PHARMACEUTICALS, INC. (US) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301145-A1 PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF BTK, SYK, LCK BTK 1/4885F10 1306/4885NR1H4 3687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.